Hematologists and oncologists from UC San Francisco shared research results and clinical guidance at the world’s premier meeting for malignant and non-malignant hematology at the American Society of ...

Human immunodeficiency virus (HIV) infections are still fairly common and an estimated 40 million people worldwide are ...

At ASH 2025, iMMagine-1 data showed that anito-cel has a favorable and durable safety profile with low rates of severe CRS, neurotoxicity, and infections.

Drs Joseph Mikhael and Shaji Kumar discuss the future of multiple myeloma, including enhanced diagnostics for detecting ...

Johnson & Johnson (NYSE:JNJ), the worldwide leader in multiple myeloma, today announced new data from the investigational Phase 3 MajesTEC-3 study that demonstrate the potential of TECVAYLI® ...

Applications for The Jockey Club's paid internship program for college students and recent college graduates and its five academic scholarships opened today. The internship program will accommodate up ...

Pivekimab sunirine (PVEK) targets CD123, showing promise in treating BPDCN, a rare aggressive blood cancer with limited treatment options. The CADENZA trial reported a 70% complete remission rate in ...

Oct 3 (Reuters) - Rocket Pharmaceuticals (RCKT.O), opens new tab said on Friday it has withdrawn its application for U.S. approval of its experimental gene therapy for a rare inherited blood disorder.

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant plasma-cell disorder present in approximately 5% of the general population over the age of 50 years. MGUS is characterized ...

Worldwide clinical PERIBLOOD™ trial by the Weizmann Institute to evaluate single cell RNA sequencing from blood as a Non-Invasive Path for Blood Disorder Diagnosis, complementing bone marrow ...